NEW BRUNSWICK, NJ–Johnson & Johnson (J&J), the world’s largest maker of healthcare products, was close to buying Sunnyvale, California-based cancer drugmaker Pharmacyclics, but came up short in a highly competitive bidding war.
On March 4, AbbVie announced it had agreed to buy Pharmacyclics for about $21 billion.
According to the Financial Times, which did note that the talks with J&J "could still fall apart," the J&J offer was expected to value Pharmacyclics near its $17.5 billion market value or at a premium.